What are the recommended dosage, indications, contraindications, and monitoring guidelines for the AREDS2 supplement in patients with intermediate or advanced age‑related macular degeneration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

AREDS2 Vitamins: Dosage, Indications, and Clinical Guidelines

The AREDS2 formulation (500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, 2 mg copper, 10 mg lutein, and 2 mg zeaxanthin) should be prescribed for patients with bilateral intermediate AMD or advanced AMD in one eye, as this reduces progression to late AMD by approximately 28%. 1, 2

Recommended Dosage

The evidence-based AREDS2 formulation consists of:

  • Vitamin C: 500 mg
  • Vitamin E: 400 IU
  • Zinc: 25 mg (reduced from original 80 mg with equivalent efficacy)
  • Copper: 2 mg (required to prevent copper-deficiency anemia when taking zinc)
  • Lutein: 10 mg
  • Zeaxanthin: 2 mg
  • Beta-carotene: OMITTED (replaced with lutein/zeaxanthin due to lung cancer risk in smokers)

1, 3, 2

Specific Indications

Prescribe AREDS2 supplements for:

  • Bilateral intermediate AMD (bilateral large drusen with or without pigment changes) - AREDS category 3
  • Advanced AMD in one eye with intermediate AMD in the fellow eye - AREDS category 4

1, 4

Do NOT prescribe for:

  • Early AMD (small drusen only) - the absolute benefit is minimal (4 fewer cases per 1000 people)
  • No AMD or minimal changes
  • Pediatric patients (not studied)

2

Contraindications and Precautions

Absolute Contraindications

  • Current smokers should NOT receive beta-carotene due to 28% increased relative risk of lung cancer (18% absolute difference in cumulative incidence). The AREDS2 formulation with lutein/zeaxanthin is appropriate for all patients including smokers. 1

Relative Contraindications and Monitoring Needs

Zinc-related concerns:

  • History of recurrent genitourinary infections or hospitalizations (7.5% vs 4.9% hospitalization rate with 80 mg zinc)
  • Prostatic hyperplasia in men
  • Stress incontinence in women
  • The 25 mg dose in AREDS2 shows no significant difference in AMD progression compared to 80 mg, with improved safety profile 1

Coordinate with primary care physician before initiating due to potential adverse effects and drug interactions, particularly in patients with:

  • History of genitourinary conditions
  • Multiple comorbidities
  • Polypharmacy 1

Clinical Efficacy Data

For intermediate AMD patients (higher baseline risk):

  • 78 fewer cases of late AMD per 1000 people treated (95% CI: 26-126 fewer)
  • Neovascular AMD risk reduction: OR 0.62 (95% CI 0.47-0.82)
  • Geographic atrophy risk reduction: OR 0.75 (95% CI 0.51-1.10)
  • Visual acuity loss (≥3 lines) reduction: OR 0.77 (95% CI 0.62-0.96)

2

Lutein/zeaxanthin vs beta-carotene substitution showed hazard ratios of 0.82 for late AMD progression and 0.78 for neovascular AMD in exploratory analyses. 2

Monitoring Guidelines

Follow-up intervals per AMD severity (Table 4 reference from guidelines):

  • Monitor for self-reported yellowing of skin (8.3% with antioxidants vs 6.0% without)
  • Assess for genitourinary symptoms, particularly in men
  • Screen for smoking status at every visit and actively promote cessation 1

At each follow-up visit:

  • Distance visual acuity with correction
  • Amsler grid testing
  • Stereoscopic biomicroscopic fundus examination
  • Assess compliance with supplementation
  • Review changes in medications and medical history 1

Common Pitfalls

Major compliance issue: Only 60% of eligible patients take AREDS2 supplements, with 83% of non-compliant patients reporting they were never advised of the benefit. 4 Explicitly counsel patients on the evidence and expected benefit at diagnosis.

Formulation inconsistency: Commercial supplements marketed for "macular health" often deviate significantly from AREDS2 standards (vitamin C 52.3% lower, vitamin E 61.2% lower, zinc 40.1% lower on average). 5 Prescribe specific AREDS2-compliant formulations by name, not generic "eye vitamins."

Cost barrier: 10% of patients cite cost as reason for non-compliance. 4 Discuss this proactively and explore options.

Adverse Effects Profile

Common:

  • Gastrointestinal symptoms (most frequent)
  • Self-reported skin yellowing (8.3%)

Serious but preventable:

  • Lung cancer with beta-carotene in smokers (use lutein/zeaxanthin instead)
  • Copper-deficiency anemia (prevented by including 2 mg copper)
  • Genitourinary hospitalizations with high-dose zinc (use 25 mg dose)

1, 2

Mortality: No significant effect on all-cause mortality with multivitamin supplementation (HR 0.87,95% CI 0.60-1.25) or lutein/zeaxanthin (HR 1.06,95% CI 0.87-1.31). 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.